



(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 19/00 (2006.01)  
C07K 16/28 (2006.01) C12N 15/13 (2006.01)  
C07K 16/46 (2006.01)

(21) International Application Number:

PCT/US2017/016407

(22) International Filing Date:

3 February 2017 (03.02.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/291,143 4 February 2016 (04.02.2016) US

(71) Applicant: **THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH** [US/US]; 11119 North Torrey Pines Road, Suite 100, La Jolla, California 92037 (US).

(72) Inventors: **KIM, Chanhyuk**; 11119 North Torrey Pines Road, Suite 100, La Jolla, California 92037 (US). **YOUNG, Travis**; 8012 Paseo Del Ocaso, La Jolla, California 92037 (US). **KIM, Minsoo**; 16448 Camelas Walk, San Diego, California 92127 (US). **MA, Jennifer**; 3203 Overland Avenue, Apt. 8146, Los Angeles, California 90034 (US). **PRESTA, Leonard**; 1900 Gough Street, Apt. 206, San Francisco, California 94109 (US). **SCHULTZ, Peter G.**; 1650 La Jolla Rancho Road, La Jolla, California 92037 (US).

(74) Agent: **HARDT, Ingo H.**; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

8 September 2017

(54) Title: HUMANIZED ANTI-CD3 ANTIBODIES, CONJUGATES AND USES THEREOF




FIG. 36B

(57) Abstract: The present invention provides for humanized anti-CD3 antibodies and conjugates thereof. These conjugates may be useful in the treatment of conditions such as prostate cancer.



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2017/016407

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61K 39/395; C07K 16/28; C07K 16/46; C07K 19/00; C12N 15/13 (2017.01)

CPC - A61K 38/00; A61K 2039/505; C07K 2317/565; C07K 2319/00 (2017.02)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

USPC - 424/133.1; 530/387.3; 530/387.1; 536/23.53; 536/23.4 (keyword delimited)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2012/0189621 A1 (DEAN et al) 26 July 2012 (26.07.2012) entire document	1-3, 23-25, 29-31, 38-40
A	US 2014/0377270 A1 (MOORE et al) 25 December 2014 (25.12.2014) entire document	1-3, 23-25, 29-31, 38-40
A	WO 2014/056783 A1 (ROCHE GLYCART AG) 17 April 2014 (17.04.2014) entire document	1-3, 23-25, 29-31, 38-40
A	WO 2014/153164 A1 (THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH et al) 25 September 2014 (25.09.2014) entire document	1-3, 23-25, 29-31, 38-40
A	WO 2007/058725 A2 (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA) 24 May 2007 (24.05.2007) entire document	1-3, 23-25, 29-31, 38-40

 Further documents are listed in the continuation of Box C. See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

05 July 2017

Date of mailing of the international search report

26 JUL 2017

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents  
P.O. Box 1450, Alexandria, VA 22313-1450  
Facsimile No. 571-273-8300

Authorized officer

Blaine R. Copenheaver

PCT Helpdesk: 571-272-4300  
PCT OSP: 571-272-7774

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2017/016407

**Box No. 1** Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
- a.  forming part of the international application as filed:  
 in the form of an Annex C/ST.25 text file.  
 on paper or in the form of an image file.
- b.  furnished together with the international application under PCT Rule 13*ter*.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
- c.  furnished subsequent to the international filing date for the purposes of international search only:  
 in the form of an Annex C/ST.25 text file (Rule 13*ter*.1(a)).  
 on paper or in the form of an image file (Rule 13*ter*.1(b) and Administrative Instructions, Section 713).
2.  In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:  
SEQ ID NOs: 51-56, 59, 74, 86, 87, 92, 96-108, 110, and 124 were searched.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2017/016407

**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  Claims Nos.: 4-22, 26-28, 32-37, 41-45  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.